Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - yfirborðs mótefna gegn inflúensuveiru (haemagglutinin og neuraminidasa) á stofn a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - bóluefni - virkt bólusetning gegn h5n1 undirgerð inflúensu a veiru. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

vbi vaccines b.v. - lifrarbólga b yfirborðs mótefnavaka - lifrarbólga b - bóluefni - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - bólusetningar gegn inflúensu - fyrirbyggjandi meðferð inflúensu af völdum a (h1n1v) 2009 veirunnar. benda ætti að vera notuð í samræmi við opinbera leiðsögn.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cz vaccines, s.a.u. - mycobacterium paratuberculosis, inactivated strain 316 f - stungulyf, fleyti - ≥ 2 mm itt avian ppd

Evrópusambandið - íslenska - EMA (European Medicines Agency)

gsk vaccines s.r.l. - ytri himnu frá neisseria meningitidis hópur b (álag nýja-sjáland 98/254), skal læknir hafa neisseria meningitidis hópur b fhbp samruna prótín, skal læknir hafa neisseria meningitidis hópur b nada prótín, skal læknir hafa neisseria meningitidis hópur b nhba samruna prótín - meningitis, meningococcal - meningókokka bóluefni - virkt ónæmisaðgerðir gegn innrásarsjúkdómum af völdum neisseria meningitidis serogroup-b stofnanna.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

gsk vaccines s.r.l. - meningókokka hóp a, c, w-135 og y samtengd bóluefni - immunization; meningitis, meningococcal - bakteríubóluefni - vialsmenveo er ætlað fyrir virk bólusetningar sem börn (frá tveggja ára aldri), unglingum og fullorðnir í hættu af völdum neisseria meningitidis tekur, c, w135 og y, til að koma í veg fyrir innrásar sjúkdómur. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

ceva santé animale - óvirkt coxiella burnetii bóluefni, stofn nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

gedeon richter plc.* - estradiolum inn - leggangatafla - 10 míkróg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

viatris limited - tadalafil - háþrýstingur, lungnabólga - Þvaglát - talmanco er ætlað í fullorðnir fyrir meðferð lungum slagæð háan blóðþrýsting (pah) flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

shionogi b.v. - ospemifene - postmenopause - hormón kynlíf og stillum kynfæri - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.